Lodamin

Lodamin is an orally bioavailable, antiangiogenic polymer-drug conjugate consisting of TNP-470 (a synthetic analog of fumagillin) conjugated to a monomethoxy-poly(ethylene glycol)-poly(lactic acid) (mPEG-PLA) copolymer. It functions as a potent inhibitor of methionine aminopeptidase 2 (MetAP2), an enzyme essential for endothelial cell proliferation and angiogenesis. Developed to overcome the severe neurotoxicity and short half-life that led to the clinical failure of the parent compound TNP-470, Lodamin forms micelles that protect the drug from degradation and allow for oral administration. Preclinical studies have demonstrated its efficacy in reducing the growth of various human xenografts, including glioblastoma, breast cancer, and hepatocarcinoma, as well as inhibiting choroidal neovascularization in animal models.

Other names

mPEG-PLA-TNP-470mPEG-PLA-TNP470mPEG-PLA-TNP 470PEG-PLA-TNP-470PEG-PLA-TNP470PEG-PLA-TNP 470